Loading...
ONCO logo

Onconetix, Inc.NasdaqCM:ONCO Stock Report

Market Cap US$3.9m
Share Price
n/a
1Y-99.6%
7D-0.9%
1D-2.7%
Portfolio Value
​
View

Onconetix, Inc.

NasdaqCM:ONCO Stock Report

Market Cap: US$3.9m

Onconetix (ONCO) Stock Overview

A biotechnology company, focuses on the research, development, and commercialization of solutions for men’s health and oncology in the United States, the European Union, and Non-European Union. More details

ONCO fundamental analysis
Snowflake Score
Valuation1/6
Future Growth0/6
Past Performance0/6
Financial Health3/6
Dividends0/6

Risk Analysis

Earnings have declined by 37.3% per year over past 5 years

Shareholders have been substantially diluted in the past year

Highly volatile share price over the past 3 months compared to the US market

Has less than 1 year of cash runway

+ 2 more risks

ONCO Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

NEW501,009 members

Join community and earn perks

Gain real feedbackFrom our editorial team, personally. Not silence.
Grow your followingReal investors. The kind who actually invest, not scroll past.
Unlock free accessFree premium subscription for consistent and quality authors.
Learn moreCreate Narrative
BL
BlackGoat
IN
Investingwilly
RO
RockeTeller
AG
Agricola
501,009 investors already sharing narratives
View all narratives

Onconetix, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Onconetix
Historical stock prices
Current Share PriceUS$1.07
52 Week HighUS$270.00
52 Week LowUS$0.88
Beta2.68
1 Month Change5.94%
3 Month Change-91.23%
1 Year Change-99.56%
3 Year Change-99.90%
5 Year Changen/a
Change since IPO-99.90%

Recent News & Updates

Recent updates

Analysis Article • Jan 24

Here's Why We're Not Too Worried About Blue Water Vaccines' (NASDAQ:BWV) Cash Burn Situation

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Seeking Alpha • Oct 11

Blue Water plans to evaluate BWV-201 vaccine for pneumococcal pneumonia

Blue Water Vaccines (NASDAQ:BWV) said it plans to evaluate BWV-201, its Streptococcus pneumoniae ((SP) vaccine candidate to prevent acute otitis media (AOM), to also protect against non-invasive pneumococcal pneumonia. Otitis media is inflammation in the middle ear. SP are gram-positive anaerobic bacteria. Non-invasive forms of pneumococcal disease include AOM, sinusitis, and pneumococcal pneumonia, while invasive forms include bacteremia, sepsis, and pneumococcal meningitis, the company said in an Oct. 11 press release. Blue Water noted that BWV-201 is a live attenuated bacterial vaccine candidate developed to prevent AOM in children caused by SP. New data, based on experiments at St. Jude Children’s Research Hospital, suggested that BWV-201 may also provide protection against pneumococcal pneumonia by limiting the ability of SP to infect the lungs. "With this new data, we believe our vaccine can provide protection across all Streptococcus pneumoniae strains and eliminate the need for antibiotic treatment associated with pneumococcal pneumonia," said Blue Water Chairman and CEO Joseph Hernandez.
Seeking Alpha • Aug 17

Blue Water Vaccines stock jumps ~22% premarket on plans to develop monkeypox shot

U.S. vaccine maker Blue Water Vaccines (NASDAQ:BWV) on Wednesday said it plans to potentially develop a monkeypox shot using its technology, sending its shares surging 22.4% to $3.12 in premarket trading. Cincinnati, Ohio.-based BWV said it would develop the vaccine using its norovirus shell and protrusion virus-like particle platform. The company is already using the platform to develop vaccines for multiple diseases, including flu and malaria. Blue Water's (BWV) announcement comes at a time when the current monkeypox outbreak has been declared a public emergency by both the U.S. FDA and the World Health Organization. According to the U.S. Centers for Disease Control and Prevention, there are a total of about 12.7K confirmed monkeypox cases as of Aug. 16 across the country. The U.S. is using two vaccines for the prevention of monkeypox - Bavarian Nordic's (OTCPK:BVNKF) (OTCPK:BVNRY) Jynneos shot and Sanofi's (SNY) ACAM2000 shot. Other vaccine developers targeting monkeypox: Emergent BioSolutions (EBS), Chimerix (CMRX).
Seeking Alpha • Jul 20

Blue Water Vaccines in pact to study Alzheimer’s vaccine

Newly IPO’d biotech Blue Water Vaccines (NASDAQ:BWV) announced a sponsored research agreement with Cincinnati Children’s Hospital Medical Center on Wednesday to study vaccine candidates for conditions such as Alzheimer’s. The news sent company shares more than 11% higher in late trading. In July 2021, Cincinnati Children’s and Blue Water Vaccines (BWV) inked a global licensing agreement to jointly develop vaccines targeted at multiple indications using the Medical Center's virus-like particle (VLP) vaccine platform. Under the previous agreement, the parties have led studies for BWV-301 in gastroenteritis caused by norovirus or rotavirus. With the new partnership, Blue Water Vaccines (BWV) has agreed to fund studies to explore the potential of the platform in other conditions such as influenza and Alzheimer’s disease. Since its public debut in February, the Cincinnati, Ohio-based vaccine developer has lost ~97%, as shown in this graph.
Seeking Alpha • May 17

Blue Water Vaccines: Estimates And Expectations

Blue Water Vaccines has a long road ahead of it. The company has multiple drug candidates in its pipeline but has not yet started clinical trials. Getting any particular vaccine through phase 3 trials will likely cost at least $40mm and take at least six years. On the positive side, vaccines have one of the highest approval probabilities of any type of drug. The expected value of an investment today is positive, but the odds of success are only about 33%.

Shareholder Returns

ONCOUS BiotechsUS Market
7D-0.9%2.3%0.8%
1Y-99.6%42.3%20.2%

Return vs Industry: ONCO underperformed the US Biotechs industry which returned 42.3% over the past year.

Return vs Market: ONCO underperformed the US Market which returned 20.2% over the past year.

Price Volatility

Is ONCO's price volatile compared to industry and market?
ONCO volatility
ONCO Average Weekly Movement26.6%
Biotechs Industry Average Movement10.3%
Market Average Movement7.3%
10% most volatile stocks in US Market16.7%
10% least volatile stocks in US Market3.2%

Stable Share Price: ONCO's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: ONCO's weekly volatility (27%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
20182David Whitewww.onconetix.com

Onconetix, Inc., a biotechnology company, focuses on the research, development, and commercialization of solutions for men’s health and oncology in the United States, the European Union, and Non-European Union. The company offers Proclarix, an in vitro protein-based blood diagnostic test for prostate cancer. It has a license agreement with LabCorp to develop and commercialize Proclarix and other products; and with Immunovia AB for the development, manufacturing, and commercialization of the PancreaSure test.

Onconetix, Inc. Fundamentals Summary

How do Onconetix's earnings and revenue compare to its market cap?
ONCO fundamental statistics
Market capUS$3.86m
Earnings (TTM)-US$10.03m
Revenue (TTM)US$735.20k
5.4x
P/S Ratio
-0.4x
P/E Ratio

Is ONCO overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
ONCO income statement (TTM)
RevenueUS$735.20k
Cost of RevenueUS$149.77k
Gross ProfitUS$585.43k
Other ExpensesUS$10.62m
Earnings-US$10.03m

Last Reported Earnings

Mar 31, 2026

Next Earnings Date

n/a

Earnings per share (EPS)-2.72
Gross Margin79.63%
Net Profit Margin-1,364.24%
Debt/Equity Ratio2.1%

How did ONCO perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/07/08 02:33
End of Day Share Price 2026/07/07 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Onconetix, Inc. is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Vernon BernardinoH.C. Wainwright & Co.
Jason McCarthyMaxim Group